Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEAYA Biosciences, Inc.IDYA · Entity 4069 | Chief Financial Officer | January 30, 2026 | February 03, 2026 |
| Scribe Therapeutics, Inc.SCTX · Entity 5494 | Director | July 23, 2026 | July 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEAYA Biosciences, Inc.
Report date January 30, 2026 · Filed February 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.19 · Expires 2036-01-30 | Direct | 170,000 |
Reported balance
After 2026-01-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-30 · Grant · Acquired 170,000 · Balance 170,000 F1: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
Scribe Therapeutics, Inc.
Report date July 23, 2026 · Filed July 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2036-07-22 | Direct | 14,725 |
Reported balance
After 2026-07-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-23 · Grant · Acquired 14,725 · Balance 14,725 F1: The options will vest as to 1/3 of the total shares on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options will vest as to 1/3 of the total shares on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 23, 2026 Filed Jul 28, 2026 01:22 UTC | Scribe Therapeutics, Inc. SCTX · Entity 5494 | GrantStock Option (Right to Buy) · Derivative | 14,725 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0002075052-26-000004 · form4-07282026_010701.xml · derivative · entry 1 Bleharski Joshua · CIK 0002075052 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,725 Underlying: Common Stock · 14,725 shares Expires 2036-07-22 F1 · derivative.exercise_date: The options will vest as to 1/3 of the total shares on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 01:05 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 170,000 | $0.00 Strike: $32.19 | $0.00 |
DisclosureSEC source: 0001610717-26-000038 · form4.xml · derivative · entry 1 Bleharski Joshua · CIK 0002075052 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2036-01-30 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.